Cefditoren

Cefditoren
Systematic (IUPAC) name
(7R)-7-((Z)-2-(2-Aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((Z)-2-(4-methylthiazol-5-yl)vinyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
Trade names Spectracef
AHFS/Drugs.com monograph
MedlinePlus a605003
Identifiers
104145-95-1 
J01DD16
PubChem CID 9870843
DrugBank DB01066 Yes
ChemSpider 8046534 Yes
UNII 81QS09V3YW Yes
KEGG D07639 
ChEBI CHEBI:59343 Yes
ChEMBL CHEMBL610374 
Chemical data
Formula C19H18N6O5S3
506.58 g/mol
  (what is this?)  (verify)

Cefditoren is a third-generation cephalosporin antibiotic for oral use. It is commonly marketed under the trade name Spectracef by Vansen Pharma Inc.

Cefditoren is also marketed under the name Meiact by Meiji Seika Pharma Co., Ltd.[1]

Spectrum of bacterial susceptibility

Cefditoren has a broad spectrum of activity and has been used to treat bacterial infections of the skin and respiratory tract, including bronchitis, pneumonia, and tonsillitis. The following represents MIC susceptibility data for a few medically significant microorganisms.

Cefditoren is a broad-spectrum antibiotic against Gram-negative and Gram-positive bacteria, but does not have antibacterial activity against Pseudomonas aeruginosa.[3]

Clinical use

Main article: Cephalosporin

Indications

Cefditoren is used to treat uncomplicated skin and skin structure infections, community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, pharyngitis, and tonsillitis.

Formulations

Cefditoren is available as 200- and 400-mg tablets. It can be formulated as the prodrug cefditoren pivoxil.

Chemical structure of cefditoren pivoxil

References

External links